Peer-reviewed veterinary case report
Canine gastrointestinal sarcomas outcomes and key signs
By Del Alcazar, Chelsea M et al.·Published in Veterinary and comparative oncology·2021·University of Pennsylvania School of Veterinary Medicine Philadelphia, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome, prognostic factors and histological characterization of canine gastrointestinal sarcomas.
- Species:
- dog
Plain-English summary
A dog diagnosed with gastrointestinal sarcoma, a type of tumor affecting the digestive system, was treated surgically. Researchers looked at 47 cases and found that the average survival time for dogs with these tumors was about 1024 days. They discovered that dogs with a lower mitotic count (a measure of how quickly the tumor cells are dividing) and those that had complete surgical removal of the tumor tended to live longer. Additionally, the level of a specific protein (c-KIT) in the tumor was linked to survival, with dogs showing stronger staining for this protein living significantly longer.
People also search for: dog gastrointestinal tumor treatment · canine sarcoma survival rate · c-KIT staining in dogs
Abstract
Canine gastrointestinal sarcomas, a group of tumours that includes leiomyosarcomas (LMSAs), gastrointestinal stromal tumours (GISTs) and other rarer sarcomas, comprise about 10-30% of all gastrointestinal tumours. This study aims to characterize the histologic characteristics and clinical behaviour in order to identify prognostic factors predictive of outcome. A single institution database search for surgically treated gastrointestinal sarcomas yielded 47 cases with adequate tissue remaining for histologic analysis and 42 cases available for analysis of clinical outcome. Tumours were then prospectively evaluated for mitotic count, necrosis, haemorrhage and inflammation, as well as categorized via immunohistochemical (IHC) staining for smooth muscle actin, c-KIT and DOG-1. IHC analysis defined 32 tumours as GISTs, 14 as LMSAs and one as a sarcoma not otherwise specified. For both GISTs and LMSAs, the overall median survival time (MST) is 1024 days (range 31-1456), which did not differ statistically between tumour types (p = .92). The overall metastatic rate of GISTs in this study was 32.1% (n = 9) which was not significantly different to that of LMSAs at 15.3% (n = 2, p = .45). In multivariate analysis, mitotic count under 9 in GIST patients and complete surgical excision in all tumour types correlated with improved MST. For patients with GISTs, the intensity of c-KIT staining also correlated positively with survival, with an MST of 250 days in cases with weak staining and an MST of 1418 days in cases with moderate or strong c-KIT staining (p = .005).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33774909/